Quality-controlled organoids are manufactured at scale for high-throughput screening, leveraging proprietary bioreactor and bioprocess technology to produce reliable and predictive patient-derived organoids (PDOs).
“Our new SpectraMax iD5e and SpectraMax iD3s readers are designed to meet the evolving needs of modern laboratories, support the holistic exploration of cellular processes through advanced multi-omics research, and enable customers to push the boundaries of complex biology.”
– Mary Duseau
President
